Skip to content
The Policy VaultThe Policy Vault

Alecensa (alectinib) — Medica

Non-Small Cell Lung Cancer – Advanced or Metastatic Disease

Initial criteria

  • age ≥ 18 years
  • anaplastic lymphoma kinase (ALK)-positive disease
  • mutation detected by an approved test

Approval duration

1 year